Skip to main content
TTrialFinderData
TrialFinderData is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Drug Resistant Epilepsy Clinical Trials

Reviewed by TrialFinderData Editorial Team · Updated

9 recruiting trials for Drug Resistant Epilepsy. Eligibility criteria explained in plain English.

TrialFinderData lists 9 Drug Resistant Epilepsy clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.

Every phased trial in this set is Phase 1 / Phase 2 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.

Research is led by Taipei Veterans General Hospital, Taiwan (1), University Hospital, Grenoble (1), Beth Israel Deaconess Medical Center (1), among the most active sponsors registered for these trials.

The most frequently studied intervention is Exablate 4000 Transcranial MRgfUS System (device, 1 trial), followed by mindfulness intervention, psycho educative programme.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
9
Total Trials
9
Recruiting Now
0
Phase 3 Trials
9
Sponsors

Track Drug Resistant Epilepsy trials

Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.

Recruiting Trials

Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.

RECRUITINGNCT06292494

Focused Ultrasound for Drug-resistant Epilepsy

Focused ultrasound (FUS) has been shown to differentially lesion or modulate (excite and inhibit) brain circuit and neural activity across a broad range of acoustic stimulus...

Sponsor: Taipei Veterans General Hospital, TaiwanEnrolling: 201 location
RECRUITINGNCT04126369

Impact of Mindfulness Intervention on Quality of Life in Patients With Drug-resistant Epilepsy.

This study evaluates a mindfulness intervention in patients with drug resistant epilepsy. Half of participants will follow a mindfulness programme, while the other half will...

Sponsor: University Hospital, GrenobleEnrolling: 1003 locations
RECRUITINGNCT07145489

Infrared Photobiomodulation in Humans With Epilepsy

Drug-resistant epilepsy represents roughly 40% of people with epilepsy. It is very challenging to stop seizures in this condition, and the treatment options are limited. This...

Sponsor: Beth Israel Deaconess Medical CenterEnrolling: 131 location
RECRUITINGPhase 1 / Phase 2NCT06388707

A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With...

This will be a prospective, open-label, single-arm, multi-center, pilot study to evaluate the safety, tolerability, and preliminary efficacy of low-intensity focused ultrasound...

Sponsor: NaviFUS CorporationEnrolling: 83 locations
RECRUITINGNCT06537986

A Neuro-cognitive and Psychosocial Intervention Module in People With Epilepsy

Patients with epilepsy, especially drug-resistant epilepsy, have a lot of cognitive \& psycho-social issues. There is little evidence pertaining to the efficacy of the various...

Sponsor: Post Graduate Institute of Medical Education and Research, ChandigarhEnrolling: 601 location
RECRUITINGNCT05393518

Electroclinical Correlation of Anxiety

Anxiety disorders have the highest prevalence among mental disorders and cause considerable individual and financial costs. Current treatments do not relieve mental suffering of...

Sponsor: University Hospital, BordeauxEnrolling: 301 location
RECRUITINGNCT06309251

Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients

The goal of this observational study is to learn about the clinical and nutritional effectiveness of ketogenic diet (KD) in pediatric patients with genetic, neurological or...

Sponsor: Danone Nutricia SpA Società BenefitEnrolling: 1003 locations
RECRUITINGNCT06432907

StereoEEG Motor Neuronal Potentials Decoding

The goals of this study are (1) to evaluate the rate of stereoEEG brain-computer interface (BCI) classification accuracy and (2) to collect the dataset of neuronal signals...

Sponsor: Research Center of Neurology, RussiaEnrolling: 301 location
RECRUITINGNCT06724029

Neurosurgical Outcome Network

The evaluation of neurosurgical outcomes varies from center to center, and the predictive factors that determine these outcomes are not fully known or shared. This study aims to...

Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo BestaEnrolling: 450020 locations

Frequently Asked Questions

There are currently 9 clinical trials for Drug Resistant Epilepsy, with 9 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.

To join a clinical trial for Drug Resistant Epilepsy, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.

Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Drug Resistant Epilepsy, representing treatments closest to potential FDA approval.

Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.

Sources: ClinicalTrials.gov, FDA
Last updated:

Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.